Generic Name: zanubrutinib

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: BeiGene

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Brukinsa is a BTK kinase inhibitor approved the previously treated adults with mantle cell lymphoma.

General Info

Brukinsa inhibits Bruton’s tyrosine kinase (BTK), which plays a role in maturation of B cell, which grow out of control or do not function normally in people with leukemia or lymphoma.

Brukinsa received accelerated approval based on results from a Phase II clinical trial of people with relapsed or refractory (nonresponsive) mantel cell lymphoma. Treatment with Brukinsa led to an overall response rate—meaning complete or partial tumor shrinkage—of 84%.


Dosing Info:

Brukinsa is taken as a capsule twice daily, with or without food.

Side Effects

Common side effects include skin rash, diarrhea and cough. Brukinsa can cause a decrease in white blood cells (neutropenia), which can lead to infections, and platelets (thrombocytopenia), which can lead to easy bleeding and bruising. Less common but more serious adverse events may include severe blood cell depletion, heavy bleeding, opportunistic infections, heart rhythm abnormalities and an increased risk of developing other cancers. Brukinsa may cause fetal harm if used during pregnancy.

For More Info:

Patient Assistance Program Info:

Last Reviewed: November 23, 2019